Ipilimumab, a cancer immunotherapy, reduced scar formation and promoted tissue regeneration in a mouse model of idiopathic ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.

Here is a recap of every FDA approval announced by the regulatory agency in the month of April, spanning various cancer types ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

A Dutch study finds that rechallenging advanced melanoma patients with ipilimumab and nivolumab (IPINIVO) can lead to ...

Sandoz has exclusive commercial rights for a biosimilar of ipilimumab in Australia, Canada, Europe, Japan and the United ...

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1]Henlius to ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

AVEO Oncology, an LG Chem company ("AVEO"), a biopharmaceutical company committed to providing differentiated solutions to ...

Dr. Kazuyuki Numakura presented a study of primary resistance to nivolumab + ipilimumab therapy affecting second-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients. Long-term ...